60 Degrees Pharmaceuticals Reports Positive Results in Five Babesiosis Study Patients

What happened

60 Degrees Pharmaceuticals reported that all five patients who completed its expanded access study for relapsing babesiosis improved and tested negative for Babesia on conventional PCR, a standard lab test. Four of the five also tested negative on a more sensitive blood-donor NAT test.

Confirmed

Global impact / market context

Positive results in a small study can support the company's case in planned FDA talks, but five patients is very limited evidence. If larger studies confirm these findings, the treatment could gain a path toward approval and eventual revenue.

Analyst inference

Investors weighing this stock must balance encouraging early data against the risk that tiny studies often fail to repeat in larger randomized trials. The company has no approved product revenue from this program yet, so future trial results drive its value.

Analyst inference

What to watch

1. Two more patients remain on treatment, bringing enrollment to seven, and the study stays open pending possible FDA discussions. Confirmed
2. The company plans to unblind its separate randomized babesiosis study in January 2027, which means revealing which patients received the treatment versus a comparison. Proposed
3. Watch whether the larger randomized study repeats the positive results, since failure there would undercut the small expanded access findings. Analyst inference

Evidence

• Original source link unavailable